Positive Response with Repeat Rifaximin Treatment in IBS-D

Salix announced results from the Phase 3 TARGET 3 trial evaluating the use of repeat treatment with rifaximin 550mg in patients with irritable bowel syndrome with diarrhea (IBS-D).

TARGET 3 is a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of repeat treatment with rifaximin 550mg three times daily for 14 days in patients with irritable bowel syndrome with diarrhea (IBS-D), who respond to an initial treatment course of rifaximin 550mg.

RELATED: New Assay to Diagnose, Differentiate IBD and IBS

Results demonstrated that a statistically significant greater proportion of patients treated with rifaximin compared to placebo responded to repeat treatment as assessed by the composite primary endpoints of IBS-related abdominal pain and stool consistency during the 4-week treatment-free follow-up period in the Double Blind Repeat Treatment Phase.

Xifaxan (rifaximin) is already approved for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥18 years of age.

For more information call (800) 508-0024 or visit Salix.com.